Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels

Lung Cancer(2024)10.1016/j.lungcan.2024.107510Source: DataRank Database

Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels is a research paper published in Lung Cancer (2024). On theSindex it has a DataRank of 0.510. It has been cited 29 times.

N/A

0.510DataRank · unranked

Scored on demand from live citation data

Open Access29 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 5.21)OA: greenTopics (38)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.510

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (6)

Elizabeth A. Handorf ORCID,Yunyun Zhou ORCID,Hossein Borghaei ORCID,Charu Aggarwal ORCID,Jessica R. Bauman ORCID

Live enrichment

PubMed:38432028 PMC:PMC11194721 OpenAlex:https://openalex.org/W4392137017

National Cancer Institute

Grant: P30CA006927

National Institutes of Health

FWCI

5.21

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11194721/pdf/nihms-1974477.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0169500224000436?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0169500224000436?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11194721

Fields of Study

Cancer Immunotherapy and BiomarkersChronic Lymphocytic Leukemia ResearchLung Cancer Treatments and MutationsHumansLung NeoplasmsImmune Checkpoint InhibitorsProto-Oncogene Proteins p21(ras)B7-H1 AntigenCohort StudiesKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Carcinoma, Non-Small-Cell LungProtein Serine-Threonine KinasesMutationAMP-Activated Protein Kinase Kinases

MeSH Terms

Kelch-Like ECH-Associated Protein 1Immune Checkpoint InhibitorsAMP-Activated Protein Kinase KinasesCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsMutationCohort StudiesProto-Oncogene Proteins p21(ras)Protein Serine-Threonine KinasesNF-E2-Related Factor 2B7-H1 Antigen

Keywords

MedicineSTK11KRASNivolumabOncologyInternal medicineImmunotherapyCancerNon small cell lung cancerKras MutationReal World Data